 | • レポートコード：MRC2Q12-18918 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、CART細胞療法剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 CART細胞療法剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 CART細胞療法剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 CART細胞療法剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのCART細胞療法剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のCART細胞療法剤の売上および2028年までの予測に焦点を当てています。 CART細胞療法剤のグローバル主要企業には、Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、CARsgen Therapeutics、Autolus Therapeutics、Sorrento Therapeutics、Mustang Bio、Bluebird Bio、Cellectis、Allogene Therapeutics、Celyadなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 CART細胞療法剤市場は、タイプとアプリケーションによって区分されます。世界のCART細胞療法剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 CD19標的、BCMA標的 【アプリケーション別セグメント】 リンパ腫、多発性骨髄腫 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - CART細胞療法剤製品概要 - タイプ別市場（CD19標的、BCMA標的） - アプリケーション別市場（リンパ腫、多発性骨髄腫） - 調査の目的 ・エグゼクティブサマリー - 世界のCART細胞療法剤販売量予測2017-2028 - 世界のCART細胞療法剤売上予測2017-2028 - CART細胞療法剤の地域別販売量 - CART細胞療法剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別CART細胞療法剤販売量 - 主要メーカー別CART細胞療法剤売上 - 主要メーカー別CART細胞療法剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（CD19標的、BCMA標的） - CART細胞療法剤のタイプ別販売量 - CART細胞療法剤のタイプ別売上 - CART細胞療法剤のタイプ別価格 ・アプリケーション別市場規模（リンパ腫、多発性骨髄腫） - CART細胞療法剤のアプリケーション別販売量 - CART細胞療法剤のアプリケーション別売上 - CART細胞療法剤のアプリケーション別価格 ・北米市場 - 北米のCART細胞療法剤市場規模（タイプ別、アプリケーション別） - 主要国別のCART細胞療法剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのCART細胞療法剤市場規模（タイプ別、アプリケーション別） - 主要国別のCART細胞療法剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のCART細胞療法剤市場規模（タイプ別、アプリケーション別） - 主要国別のCART細胞療法剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のCART細胞療法剤市場規模（タイプ別、アプリケーション別） - 主要国別のCART細胞療法剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのCART細胞療法剤市場規模（タイプ別、アプリケーション別） - 主要国別のCART細胞療法剤市場規模（トルコ、サウジアラビア） ・企業情報 Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、CARsgen Therapeutics、Autolus Therapeutics、Sorrento Therapeutics、Mustang Bio、Bluebird Bio、Cellectis、Allogene Therapeutics、Celyad ・産業チェーン及び販売チャネル分析 - CART細胞療法剤の産業チェーン分析 - CART細胞療法剤の原材料 - CART細胞療法剤の生産プロセス - CART細胞療法剤の販売及びマーケティング - CART細胞療法剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - CART細胞療法剤の産業動向 - CART細胞療法剤のマーケットドライバー - CART細胞療法剤の課題 - CART細胞療法剤の阻害要因 ・主な調査結果 |
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for CAR T-Cell Therapy Agents estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for CAR T-Cell Therapy Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for CAR T-Cell Therapy Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for CAR T-Cell Therapy Agents is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of CAR T-Cell Therapy Agents include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the CAR T-Cell Therapy Agents companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional CAR T-Cell Therapy Agents market. Further, it explains the major drivers and regional dynamics of the global CAR T-Cell Therapy Agents market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
CAR T-Cell Therapy Agents Segment by Type
CD19-targeted
BCMA-targeted
CAR T-Cell Therapy Agents Segment by Application
Lymphoma
Multiple Myeloma
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the CAR T-Cell Therapy Agents market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for CAR T-Cell Therapy Agents market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of CAR T-Cell Therapy Agents, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for CAR T-Cell Therapy Agents, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CAR T-Cell Therapy Agents revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global CAR T-Cell Therapy Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for CAR T-Cell Therapy Agents revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of CAR T-Cell Therapy Agents in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy Agents companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR T-Cell Therapy Agents revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR T-Cell Therapy Agents Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CD19-targeted
1.2.3 BCMA-targeted
1.3 Market by Application
1.3.1 Global CAR T-Cell Therapy Agents Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy Agents Market Perspective (2017-2028)
2.2 CAR T-Cell Therapy Agents Growth Trends by Region
2.2.1 CAR T-Cell Therapy Agents Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 CAR T-Cell Therapy Agents Historic Market Size by Region (2017-2022)
2.2.3 CAR T-Cell Therapy Agents Forecasted Market Size by Region (2023-2028)
2.3 CAR T-Cell Therapy Agents Market Dynamics
2.3.1 CAR T-Cell Therapy Agents Industry Trends
2.3.2 CAR T-Cell Therapy Agents Market Drivers
2.3.3 CAR T-Cell Therapy Agents Market Challenges
2.3.4 CAR T-Cell Therapy Agents Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy Agents Players by Revenue
3.1.1 Global Top CAR T-Cell Therapy Agents Players by Revenue (2017-2022)
3.1.2 Global CAR T-Cell Therapy Agents Revenue Market Share by Players (2017-2022)
3.2 Global CAR T-Cell Therapy Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR T-Cell Therapy Agents Revenue
3.4 Global CAR T-Cell Therapy Agents Market Concentration Ratio
3.4.1 Global CAR T-Cell Therapy Agents Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy Agents Revenue in 2021
3.5 CAR T-Cell Therapy Agents Key Players Head office and Area Served
3.6 Key Players CAR T-Cell Therapy Agents Product Solution and Service
3.7 Date of Enter into CAR T-Cell Therapy Agents Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-Cell Therapy Agents Breakdown Data by Type
4.1 Global CAR T-Cell Therapy Agents Historic Market Size by Type (2017-2022)
4.2 Global CAR T-Cell Therapy Agents Forecasted Market Size by Type (2023-2028)
5 CAR T-Cell Therapy Agents Breakdown Data by Application
5.1 Global CAR T-Cell Therapy Agents Historic Market Size by Application (2017-2022)
5.2 Global CAR T-Cell Therapy Agents Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America CAR T-Cell Therapy Agents Market Size (2017-2028)
6.2 North America CAR T-Cell Therapy Agents Market Size by Type
6.2.1 North America CAR T-Cell Therapy Agents Market Size by Type (2017-2022)
6.2.2 North America CAR T-Cell Therapy Agents Market Size by Type (2023-2028)
6.2.3 North America CAR T-Cell Therapy Agents Market Share by Type (2017-2028)
6.3 North America CAR T-Cell Therapy Agents Market Size by Application
6.3.1 North America CAR T-Cell Therapy Agents Market Size by Application (2017-2022)
6.3.2 North America CAR T-Cell Therapy Agents Market Size by Application (2023-2028)
6.3.3 North America CAR T-Cell Therapy Agents Market Share by Application (2017-2028)
6.4 North America CAR T-Cell Therapy Agents Market Size by Country
6.4.1 North America CAR T-Cell Therapy Agents Market Size by Country (2017-2022)
6.4.2 North America CAR T-Cell Therapy Agents Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy Agents Market Size (2017-2028)
7.2 Europe CAR T-Cell Therapy Agents Market Size by Type
7.2.1 Europe CAR T-Cell Therapy Agents Market Size by Type (2017-2022)
7.2.2 Europe CAR T-Cell Therapy Agents Market Size by Type (2023-2028)
7.2.3 Europe CAR T-Cell Therapy Agents Market Share by Type (2017-2028)
7.3 Europe CAR T-Cell Therapy Agents Market Size by Application
7.3.1 Europe CAR T-Cell Therapy Agents Market Size by Application (2017-2022)
7.3.2 Europe CAR T-Cell Therapy Agents Market Size by Application (2023-2028)
7.3.3 Europe CAR T-Cell Therapy Agents Market Share by Application (2017-2028)
7.4 Europe CAR T-Cell Therapy Agents Market Size by Country
7.4.1 Europe CAR T-Cell Therapy Agents Market Size by Country (2017-2022)
7.4.2 Europe CAR T-Cell Therapy Agents Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy Agents Market Size (2017-2028)
8.2 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Type
8.2.1 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Type (2017-2022)
8.2.2 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Type (2023-2028)
8.2.3 Asia-Pacific CAR T-Cell Therapy Agents Market Share by Type (2017-2028)
8.3 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Application
8.3.1 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Application (2017-2022)
8.3.2 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Application (2023-2028)
8.3.3 Asia-Pacific CAR T-Cell Therapy Agents Market Share by Application (2017-2028)
8.4 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Region
8.4.1 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Region (2017-2022)
8.4.2 Asia-Pacific CAR T-Cell Therapy Agents Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America CAR T-Cell Therapy Agents Market Size (2017-2028)
9.2 Latin America CAR T-Cell Therapy Agents Market Size by Type
9.2.1 Latin America CAR T-Cell Therapy Agents Market Size by Type (2017-2022)
9.2.2 Latin America CAR T-Cell Therapy Agents Market Size by Type (2023-2028)
9.2.3 Latin America CAR T-Cell Therapy Agents Market Share by Type (2017-2028)
9.3 Latin America CAR T-Cell Therapy Agents Market Size by Application
9.3.1 Latin America CAR T-Cell Therapy Agents Market Size by Application (2017-2022)
9.3.2 Latin America CAR T-Cell Therapy Agents Market Size by Application (2023-2028)
9.3.3 Latin America CAR T-Cell Therapy Agents Market Share by Application (2017-2028)
9.4 Latin America CAR T-Cell Therapy Agents Market Size by Country
9.4.1 Latin America CAR T-Cell Therapy Agents Market Size by Country (2017-2022)
9.4.2 Latin America CAR T-Cell Therapy Agents Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy Agents Market Size (2017-2028)
10.2 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Type
10.2.1 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Type (2017-2022)
10.2.2 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Type (2023-2028)
10.2.3 Middle East & Africa CAR T-Cell Therapy Agents Market Share by Type (2017-2028)
10.3 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Application
10.3.1 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Application (2017-2022)
10.3.2 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Application (2023-2028)
10.3.3 Middle East & Africa CAR T-Cell Therapy Agents Market Share by Application (2017-2028)
10.4 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Country
10.4.1 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Country (2017-2022)
10.4.2 Middle East & Africa CAR T-Cell Therapy Agents Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis CAR T-Cell Therapy Agents Introduction
11.1.4 Novartis Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.1.5 Novartis Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences CAR T-Cell Therapy Agents Introduction
11.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.2.5 Gilead Sciences Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Agents Introduction
11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.3.5 Bristol-Myers Squibb Recent Developments
11.4 J & J
11.4.1 J & J Company Details
11.4.2 J & J Business Overview
11.4.3 J & J CAR T-Cell Therapy Agents Introduction
11.4.4 J & J Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.4.5 J & J Recent Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Details
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics CAR T-Cell Therapy Agents Introduction
11.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.5.5 JW Therapeutics Recent Developments
11.6 FOSUNKite
11.6.1 FOSUNKite Company Details
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite CAR T-Cell Therapy Agents Introduction
11.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.6.5 FOSUNKite Recent Developments
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Details
11.7.2 CARsgen Therapeutics (Pipeline) Business Overview
11.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Agents Introduction
11.7.4 CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.7.5 CARsgen Therapeutics (Pipeline) Recent Developments
11.8 CARsgen Therapeutics
11.8.1 CARsgen Therapeutics Company Details
11.8.2 CARsgen Therapeutics Business Overview
11.8.3 CARsgen Therapeutics CAR T-Cell Therapy Agents Introduction
11.8.4 CARsgen Therapeutics Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.8.5 CARsgen Therapeutics Recent Developments
11.9 Autolus Therapeutics
11.9.1 Autolus Therapeutics Company Details
11.9.2 Autolus Therapeutics Business Overview
11.9.3 Autolus Therapeutics CAR T-Cell Therapy Agents Introduction
11.9.4 Autolus Therapeutics Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.9.5 Autolus Therapeutics Recent Developments
11.10 Sorrento Therapeutics
11.10.1 Sorrento Therapeutics Company Details
11.10.2 Sorrento Therapeutics Business Overview
11.10.3 Sorrento Therapeutics CAR T-Cell Therapy Agents Introduction
11.10.4 Sorrento Therapeutics Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.10.5 Sorrento Therapeutics Recent Developments
11.11 Mustang Bio
11.11.1 Mustang Bio Company Details
11.11.2 Mustang Bio Business Overview
11.11.3 Mustang Bio CAR T-Cell Therapy Agents Introduction
11.11.4 Mustang Bio Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.11.5 Mustang Bio Recent Developments
11.12 Bluebird Bio
11.12.1 Bluebird Bio Company Details
11.12.2 Bluebird Bio Business Overview
11.12.3 Bluebird Bio CAR T-Cell Therapy Agents Introduction
11.12.4 Bluebird Bio Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.12.5 Bluebird Bio Recent Developments
11.13 Cellectis
11.13.1 Cellectis Company Details
11.13.2 Cellectis Business Overview
11.13.3 Cellectis CAR T-Cell Therapy Agents Introduction
11.13.4 Cellectis Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.13.5 Cellectis Recent Developments
11.14 Allogene Therapeutics
11.14.1 Allogene Therapeutics Company Details
11.14.2 Allogene Therapeutics Business Overview
11.14.3 Allogene Therapeutics CAR T-Cell Therapy Agents Introduction
11.14.4 Allogene Therapeutics Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.14.5 Allogene Therapeutics Recent Developments
11.15 Celyad
11.15.1 Celyad Company Details
11.15.2 Celyad Business Overview
11.15.3 Celyad CAR T-Cell Therapy Agents Introduction
11.15.4 Celyad Revenue in CAR T-Cell Therapy Agents Business (2017-2022)
11.15.5 Celyad Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer